Literature DB >> 29705562

Body fat mass and distribution as predictors of metabolic outcome and weight loss after Roux-en-Y gastric bypass.

Daniel Eriksson Hogling1, Mikael Rydén2, Jesper Bäckdahl2, Anders Thorell3, Peter Arner2, Daniel P Andersson2.   

Abstract

BACKGROUND: Bariatric surgery such as Roux-en-Y gastric bypass (RYGB) remains the most effective treatment of obesity and associated co-morbidities. Body fat distribution associates with metabolic function.
OBJECTIVE: To investigate if preoperative body fat mass and distribution measured by dual-energy x-ray absorptiometry (DXA) predict weight loss and metabolic outcome after RYGB, and to compare predictive value of DXA with simple anthropometric measures.
SETTING: Four Swedish hospitals within the Stockholm area.
METHODS: Two hundred fifteen women scheduled for RYGB were included. Evaluations before and 2 years after RYGB included determination of insulin sensitivity by the homeostatic model assessment of insulin resistance, blood pressure, plasma lipids, and anthropometric measures, such as waist-to-hip-ratio and fat percentage estimated by formula. Body fat mass and distribution were determined by DXA.
RESULTS: Follow-up rate was 77.2% (n = 166). All clinical, anthropometric, and DXA measures were improved/reduced postsurgery (all P<.0001). Android/gynoid fat mass ratio and waist-to-hip-ratio predicted improved homeostatic model assessment of insulin resistance (P = .0028 and .0014), independently of body mass index and age. Body fat percentage, measured by DXA or estimated by formula, predicted percent weight loss (P<.0001 and .0083). Body mass index predicted percent weight loss and percent excess body mass index lost (P = .0022 and<.0001). DXA and anthropometric measures performed equally as predictors, except for DXA measured fat percentage that was slightly better than formula estimated.
CONCLUSION: DXA provided predictive values similar to those by basic anthropometric measures, suggesting a limited additional value of preoperative DXA to predict metabolic improvement and weight loss after RYGB in women.
Copyright © 2018 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Body fat; Insulin sensitivity; Metabolic syndrome; Prediction; Visceral fat; Weight loss; X-ray absorptiometry

Mesh:

Year:  2018        PMID: 29705562     DOI: 10.1016/j.soard.2018.03.012

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

1.  Mid-term bariatric surgery outcomes for obese patients: does weight matter?

Authors:  N Samuel; Q Jalal; A Gupta; Fak Mazari; P Vasas; S Balachandra
Journal:  Ann R Coll Surg Engl       Date:  2019-09-06       Impact factor: 1.891

2.  The Influence of Laparoscopic Sleeve Gastrectomy on Body Composition and Fat Distribution in Obese Caucasian Men and Women.

Authors:  Marek Tałałaj; Agata Bogołowska-Stieblich; Michał Wąsowski; Artur Binda; Paweł Jaworski; Małgorzata Wrzosek; Wiesław Tarnowski
Journal:  Obes Surg       Date:  2020-10       Impact factor: 4.129

3.  Predictors for weight loss after Roux-en-Y gastric bypass: the trend and associated factors for weight loss.

Authors:  Foolad Eghbali; Mansour Bahardoust; Abdolreza Pazouki; Gelayol Barahman; Adnan Tizmaghz; Amir Hajmohammadi; Reza Karami; Fatemeh Sadat Hosseini-Baharanchi
Journal:  BMC Surg       Date:  2022-08-11       Impact factor: 2.030

4.  Metabolic Impact of Body Fat Percentage Independent of Body Mass Index in Women with Obesity Remission After Gastric Bypass.

Authors:  Daniel Eriksson Hogling; Jesper Bäckdahl; Anders Thorell; Mikael Rydén; Daniel P Andersson
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

5.  What predicts the unsuccess of bariatric surgery? An observational retrospective study.

Authors:  C D'Eusebio; S Boschetti; F Rahimi; G Fanni; A De Francesco; M Toppino; M Morino; E Ghigo; S Bo
Journal:  J Endocrinol Invest       Date:  2020-08-25       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.